Events and Webinars

IMPORTANT SAFETY INFORMATION

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

IMPLEMENTING SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted)

GSK cordially invites you to learn about SHINGRIX. The presentation will focus on implementing SHINGRIX into your practice, and will review clinical data, patient and provider resources, and strategies to counsel patients about SHINGRIX.

Related Events and Webinars

September 17, 2019 12:15PM EST

GSK cordially invites you to learn about SHINGRIX. The presentation will focus on implementing SHINGRIX into your practice, and will review clinical data, patient and provider resources, and strategies to counsel patients about SHINGRIX.

Webinar
1h
September 18, 2019 7:15PM PST

GSK cordially invites you to learn about SHINGRIX. The presentation will focus on implementing SHINGRIX into your practice, and will review clinical data, patient and provider resources, and strategies to counsel patients about SHINGRIX.

Webinar
1h
September 25, 2019 6:15PM CST

GSK cordially invites you to learn about SHINGRIX. The presentation will focus on implementing SHINGRIX into your practice, and will review clinical data, patient and provider resources, and strategies to counsel patients about SHINGRIX.

Webinar
1h
September 26, 2019 12:15PM PST

GSK cordially invites you to learn about SHINGRIX. The presentation will focus on implementing SHINGRIX into your practice, and will review clinical data, patient and provider resources, and strategies to counsel patients about SHINGRIX.

Webinar
1h
< Page 1 >

IMPORTANT SAFETY INFORMATION

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

 

Trademarks are property of their respective owners.

1009353R0 September 2018

INDICATION

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).